ChemDmart
Chemxpert Database
  • About
    • About
    • Leadership
    • Advisory Board
  • Products
    • ChemProtel - Product Intelligence
    • CompFolio - One Company Profile
    • CompGroupe - Group Company Profile
    • ChemScape - Data Landscape
    • ChemDmart - E-Market Place
    • DataIntel - Data Analytics/Trends
    • DataFeed - Data News/Feed
    • CompShow- Company Showcase
  • Sources
  • Subscription
  • User Guide
  • Contact
  • Book Demo Log In
  1. Home
  2. All News
  3. Fda Grants Orphan Drug Designation To Zymedis Zma001
News Feed
course image
  • 01 Aug 2024
  • Admin
  • News Article

FDA Grants Orphan Drug Designation to Zymedi's ZMA001

FDA Grants Orphan Drug Designation to Zymedi's ZMA001 for Pulmonary Arterial Hypertension

Overview

Zymedi, led by CEO Sunghoon Kim, has announced that its novel antibody treatment, ZMA001, designed for pulmonary arterial hypertension (PAH), has received Orphan Drug designation from the U.S. Food and Drug Administration (FDA).

About PAH

  • PAH is a serious inflammatory vascular condition characterized by the narrowing and remodeling of pulmonary arterioles due to various factors. 
  • This disease leads to immune cells infiltrating the lungs, damaging the pulmonary system, increasing arterial pressure, and eventually causing right ventricular failure and death. 
  • The survival rate for PAH patients is comparable to that of cancer patients.

Symptoms and Cases

  • The disease initially presents with shortness of breath and progresses to symptoms like chest pain, fainting, and severe fatigue, significantly affecting daily life. 
  • Approximately 70,000 people worldwide suffer from PAH, including around 6,000 in South Korea, making it a rare condition.

PAH Treatments

  • Current PAH treatments primarily involve vasodilators, which only manage symptoms and do not cure the disease. 
  • Due to the varied causes of PAH, there is a significant need for targeted therapies.

ZMA001

  • ZMA001 is a human monoclonal antibody that works by preventing inflammation-inducing macrophages from infiltrating the lungs, thereby inhibiting the symptoms of PAH from early stages. 
  • In preclinical studies with animal models, ZMA001 demonstrated greater efficacy than existing treatments.
  • Importantly, ZMA001 has shown enhanced effects when used in combination with current medications, suggesting it could be a transformative treatment in the PAH field, where new therapies are critically needed.

Optimistic Stand from Zymedi

  • Nam Hoon Kwon, Zymedi 's CTO, expressed optimism about the Orphan Drug designation for ZMA001, stating, ""We aim to provide an essential new treatment option for PAH patients.""
  • Kwon also highlighted the advantages of the FDA's Orphan Drug designation, including tax credits for clinical trial costs, seven years of market exclusivity upon approval, and development assistance. 
  • These benefits are particularly helpful for startups with limited resources, supporting clinical advancement and commercial success.

Phase 1a Clinical Trial Proceedings

  • Zymedi commenced a Phase 1a clinical trial for ZMA001 at the NIH Clinical Center in January, involving healthy adult participants. 
  • This phase is focused on assessing the drug's safety and tolerability in humans. 
  • Early results will help determine the appropriate dosages and identify potential side effects, paving the way for subsequent clinical trial phases.

Let’s apply Data-Driven Pricing to Your APIs

Sick and tired of always wondering if you are being asked to pay the right price for your APIs? This empowers you with the answers you need to make the right decisions in the Global API market.

Chemxpert Database is one of the biggest and most comprehensive directories of pharma and chemicals, manufacturers, suppliers and information. Provided with current information on prices, demand and transactions, it gives you instant feedback on whether you are buying what is right and at the right time.

Start using market intelligence today and allow yourself to be in control in the API market.

Check it out today and make more informed sourcing decisions! Learn More!

Categories

image
Product Related Updates
image
Certificates/Accreditation
image
Approval/Launch
image
Clinical Trial Update
image
Licensing/Partnering/Collaboration Deal
image
ODD/BTA/FTA Status
image
Merger/Acquisition
image
Warning/Recalls

Lifescience Intellipedia Pvt. Ltd.

C-89, Sector-65 Noida-U.P. 201301 (India)
Toll-Free: 18004190155
Phone: +91-120-6631301-361
Mobile: +91-9990237670
Email: info@lifescienceintellipedia.com
Email: sales@lifescienceintellipedia.com

USEFUL LINKS

  • Home
  • Privacy Policy
  • Terms & Conditions
  • Terms Of Use
  • Refund Policy
  • Blogs

OUR PRODUCTS

  • ChemProtel - Product Intelligence
  • CompFolio - One Company Profile
  • CompGroupe - Group Company Profile
  • ChemScape - Data Landscape
  • ChemDmart - E-Market Place
  • DataIntel - Data Analytics/Trends
  • DataFeed - Data News/Feed
  • CompShow- Company Showcase

LOCATION

© Copyright Lifescience Intellipedia Pvt. Ltd.. All Rights Reserved

Fill The Form